Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

To the Editor We noted with interest the findings of Ben-Aharon et al regarding the application of the American Society of Clinical Oncology Net Health Benefit Criteria for tail-of-the-curve credits among immunotherapy studies. The findings do not surprise, partly because the time point of twice the median survival of the control arm in immunotherapy studies is more often at the shoulder of the curve rather than the true tail of the survival curve. This substantially compromises the ability to detect the long-term gains that are best observed at the true tail.

https://ift.tt/2ModPJ1